Médecins Dr. Pierre Maroun

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

DOI: 10.1177/1758835919853971

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic

DOI: 10.1016/j.ctro.2018.07.001

Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group

DOI: 10.1016/j.ejca.2018.04.008

Why is brachytherapy still essential in 2017?

DOI: 10.1016/j.canrad.2017.11.009

Preclinical ex vivo evaluation of the diagnostic performance of a new device for in situ label-free fluorescence spectral analysis of breast masses

DOI: 10.1007/s00330-017-5228-7

Brachytherapy for conservative treatment of invasive penile carcinoma in older patients: Single institution experience

DOI: 10.1016/j.jgo.2017.11.001

Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae

DOI: 10.18632/oncotarget.24271

Long-term evaluation of urinary, sexual, and quality of life outcomes after brachytherapy for penile carcinoma

DOI: 10.1016/j.brachy.2017.09.006

Clinical trials and perspectives of radiotherapy for uterine endometrial cancers

DOI: 10.1016/j.bulcan.2017.07.009

Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome

DOI: 10.1016/j.ijrobp.2017.02.090